Keytruda is an immunotherapy drug that is prescribed to cancer patients and is used to treat different types of cancer. It was first approved by the FDA in 2014 for the treatment of advanced or ...

Melanoma is the deadliest form of skin cancer. A new vaccine-drug combo could slash recurring cases - An estimated 112,000 ...

Moderna and Merck present 5-year data for intismeran autogene in combo with Keytruda in patients with high-risk stage III/IV melanoma following complete resection at 2026 ASCO mee ...

At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy ...

The highly anticipated study found that ivonescimab reduced the risk of death by 34% compared with another drug ...

Results from the first and second interim analyses of the Phase 3 KEYNOTE-B96 trial were selected for presentation during a Presidential Symposium session at the European Society for Medical Oncology ...

At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran ...

Health minister hopes a key injectable cancer drug will be available in all five trusts "as soon as possible".

This is the first positive Phase 3 trial for WELIREG in earlier-stage disease, the first positive results for a HIF-2α inhibitor and immunotherapy combination and the first study in earlier-stage ...

Keytruda, known scientifically as pembrolizumab, is an immunotherapy drug that has transformed cancer treatment for many patients worldwide. Traditional chemotherapy works by directly attacking the ...

J&J's Rybrevant and cancer vaccines are showing benefit During the American Society of Clinical Oncology (ASCO) meeting 2026, ...